The goal of the study is to learn what happens to levels of MK-0616 in the blood when MK-0616 is given in different forms. Researchers believe that there is no effect on a healthy person's body if MK-0616 is given in different forms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
oral administration
QPS-MRA, LLC-Early Phase
South Miami, Florida, United States
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-0616
Blood samples will be collected to determine the AUC0-inf of MK-0616.
Time frame: Predose and at designated timepoints up to 168 hours postdose
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hr) of MK-0616
Blood samples will be collected to determine the AUC0-24 of MK-0616.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-0616
Blood samples will be collected to determine the AUC0-last of MK-0616.
Time frame: Predose and at designated timepoints up to 168 hours postdose
Maximum Plasma Concentration (Cmax) of MK-0616
Blood samples will be collected to determine the Cmax of MK-0616.
Time frame: Predose and at designated timepoints up to 168 hours postdose
Maximum Plasma Concentration (C24) of MK-0616
Blood samples will be collected to determine the C24 of MK-0616.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Apparent Terminal Half-life (t1/2) of MK-0616
Blood samples will be collected to determine the apparent t1/2 of MK-0616.
Time frame: Predose and at designated timepoints up to 168 hours postdose
Time to Maximum Plasma Concentration (Tmax) of MK-0616
Blood samples will be collected at pre-specified timepoints to determine the Tmax of MK-0616.
Time frame: Predose and at designated timepoints up to 168 hours postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 2 months
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 2 months